{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:58:30Z","timestamp":1785308310994,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite statins and ezetimibe, many high-risk patients fail to reach lipid targets. Alirocumab, a PCSK9 inhibitor, is an effective alternative, but real-world data are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the real-world effectiveness of Alirocumab in improving lipid profiles among patients with established cardiovascular disease and assessed the impact of patient characteristics, comorbidities, and concurrent medications. Additionally, artificial intelligence (AI) models were explored to predict treatment outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective observational study was conducted at the Royal Commission Health Services Program in Aljubail, Saudi-Arabia. Data from 206 adults receiving Alirocumab (75\u00a0mg every 2\u00a0weeks) from July 2021 to July 2023 were analyzed. Lipid profiles were assessed at baseline, 12\u00a0weeks, and 24\u00a0weeks. Logistic regression identified factors associated with lipid target achievement. Machine learning models including Logistic-Regression, K-Neighbors, XGBoost, Support Vector Machine (SVM), Gaussian Naive Bayes, Decision Tree, and Random Forest were used to predict outcomes, and an AI-based SVM tool was developed as an exploratory research prototype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Alirocumab significantly reduced LDL-C, total cholesterol, and triglycerides while increasing HDL-C at 12 and 24\u00a0weeks (p &amp;lt; 0.001). Ezetimibe and metformin improved lipid outcomes, whereas aspirin and anticoagulants were associated with lower target achievement. AI model accuracies ranged from 0.50 to 0.63, with the SVM classifier performing best (accuracy 0.625, F1 score 0.61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Alirocumab is effective in lowering lipids in real-world cardiovascular patients. Certain medications may enhance outcomes. AI models provide moderate predictive ability, supporting potential personalized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1870914","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:32Z","timestamp":1785304712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation and AI-powered prediction of the efficacy of alirocumab use among patients with cardiovascular disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Hadeer Ehab","family":"Barakat","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy Practice, The British University in Egypt","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Selim","family":"Abougalambou","sequence":"additional","affiliation":[{"name":"Royal Commission Health Services Program (RCH) in Aljubail Industrial City","place":["Aljubail, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Maher","sequence":"additional","affiliation":[{"name":"Royal Commission Health Services Program (RCH) in Aljubail Industrial City","place":["Aljubail, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar M.","family":"Nour","sequence":"additional","affiliation":[{"name":"Department of Computer Engineering and Systems, Faculty of Engineering and Technology, Badr University in Cairo (BUC)","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam Tharwat","family":"Abdelhalim","sequence":"additional","affiliation":[{"name":"School of Information Technology and Computer Science (ITCS), Nile University","place":["Giza, Egypt"]},{"name":"Center for Informatics Science (CIS), Nile University","place":["Sheikh Zayed, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammena Y.","family":"Binsaleh","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Mohamed I.","family":"Belal","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, Faculty of Pharmacy (Girls), Al-Azhar University","place":["Cairo, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa Selim","family":"Abougalambou","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice, Ahram Canadian University","place":["Giza, Egypt"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1161\/01.cir.67.4.730","article-title":"Summary estimates of cholesterol used to predict coronary heart disease","volume":"67","author":"Castelli","year":"1983","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.rec.2017.01.002","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"74","author":"Catapano","year":"2016","journal-title":"Pol. Heart J. (Kardiologia Polska)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s43044-024-00562-7","article-title":"2024 Egyptian consensus statement on the role of Non-statin therapies for LDL cholesterol lowering in different patient risk categories","volume":"76","author":"El Din Taha","year":"2024","journal-title":"Egypt. Heart J."},{"key":"B4","volume-title":"Guidelines for the Management of High Blood Cholesterol","author":"Feingold","year":"2025"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/jcm11164701","article-title":"AFG Cicero management of high-risk hypercholesterolemic patients and PCSK9 inhibitors reimbursement policies: data from a cohort of Italian hypercholesterolemic outpatients","volume":"11","author":"Fogacci","year":"2022","journal-title":"J. Clin. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2337\/db13-0194","article-title":"Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance by brown adipose tissue in mice","volume":"63","author":"Geerling","year":"2014","journal-title":"Diabetes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.pcad.2023.02.007","article-title":"PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients","volume":"79","author":"Gunta","year":"2023","journal-title":"Prog. Cardiovasc. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1161\/ATVBAHA.120.315708","article-title":"New insight into metformin-induced cholesterol-lowering effect crosstalk between glucose and cholesterol homeostasis via ChREBP (carbohydrate-responsive element-binding protein)-mediated PCSK9 (proprotein convertase subtilisin\/kexin type 9) regulation","volume":"41","author":"Hu","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, Vascular Biology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e025936","DOI":"10.1136\/bmjopen-2018-025936","article-title":"Submissions from the SPRINT data analysis challenge on clinical risk prediction: a cross-sectional evaluation","volume":"9","author":"Jackevicius","year":"2019","journal-title":"BMJ Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/2047487320940102","article-title":"Eligibility for PCSK9 inhibitors based on the 2019 ESC\/EAS and 2018 ACC\/AHA guidelines","volume":"28","author":"Koskinas","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias: developed by the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"46","author":"Mach","year":"2025","journal-title":"Eur. Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2022.06.128","article-title":"Efficacy & safety of PCSK9-inhibitors: a systematic review and meta-analysis of real-world data","volume":"355","author":"Mulder","year":"2022","journal-title":"Atherosclerosis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.5603\/KP.2016.0120","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"74","author":"Piepoli","year":"2016","journal-title":"Pol. Heart J. (Kardiologia Polska)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1080\/14656566.2024.2406270","article-title":"Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia","volume":"25","author":"Saad ALGhasab","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/nejmoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.4103\/jfmpc.jfmpc_406_19","article-title":"Safety and efficacy of alirocumab: a meta analysis of 12 randomized controlled trials","volume":"8","author":"Shukla","year":"2019","journal-title":"J. Family Medicine Primary Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1001\/jama.1986.03380200061022","article-title":"Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356 222 primary screenees of the multiple risk factor intervention trial (MRFIT)","volume":"256","author":"Stamler","year":"1986","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e001572","DOI":"10.1136\/openhrt-2021-001572","article-title":"Intensified lipid-lowering treatment with alirocumab in patients with coronary heart disease","volume":"8","author":"Steffens","year":"2021","journal-title":"Open Heart"},{"key":"B19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.diabet.2019.101120","article-title":"Alirocumab efficacy and safety by body mass index: a pooled analysis from 10 phase 3 ODYSSEY trials","volume":"46","author":"Tinahones","year":"2020","journal-title":"Diabetes and Metabolism"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney International"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","article-title":"Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial","volume":"41","author":"Tunon","year":"2020","journal-title":"Eur. Heart Journal"},{"key":"B22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.jacl.2015.11.010","article-title":"A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality","volume":"10","author":"Wadhera","year":"2016","journal-title":"J. Clinical Lipidology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/mp.2015.221","article-title":"Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials","volume":"21","author":"Wu","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.2337\/dc15-0658","article-title":"Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes","volume":"38","author":"Xu","year":"2015","journal-title":"Diabetes Care"},{"key":"B25","doi-asserted-by":"publisher","first-page":"110599","DOI":"10.1016\/j.compbiomed.2025.110599","article-title":"Optimizing treatment to control LDL cholesterol using machine learning","volume":"195","author":"Yepez","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.jacc.2024.06.035","article-title":"Triglyceride levels, alirocumab treatment, and cardiovascular outcomes after an acute coronary syndrome","volume":"84","author":"Zahger","year":"2024","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1870914\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:58:33Z","timestamp":1785304713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1870914\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":26,"alternative-id":["10.3389\/fphar.2026.1870914"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1870914","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1870914"}}